Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, TSCAN THERAPEUTICS, INC. reported revenue of $10M, up 266.7% year over year. Operating margin was -1315.4% and net margin -1256.8%, on a free-cash-flow margin of -1353.3% with capital expenditure at 42.7% of revenue. Every figure is computed directly from TCRX's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $10M | -1315.4% | -1256.8% |
| FY2024 | $3M | -4787.7% | -4527.7% |
| FY2023 | $21M | -444.0% | -423.9% |
| FY2022 | $14M | -492.3% | -489.3% |
| FY2021 | $10M | -479.6% | -479.5% |
How does TCRX compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.